In the wake of deep R&D cuts, Bayer flags safety concerns for a top PhIII drug
Less than a week after Bayer announced plans to carve down its internal R&D group, laying off 900 R&D staffers, the German company has tipped the market that one of its crucial late-stage development efforts has run into serious trouble.
R&D chief Joerg Moeller, who gathered the reins in research after the departure of Andreas Busch in late 2017, told an investment group in London Monday that the company was halting its development work on vilaprisan, a uterine fibroid drug that has been billed as a top blockbuster prospect at the company.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters